NeuroMetrix (NASDAQ:NURO) Earns Sell Rating from Analysts at StockNews.com

Equities research analysts at StockNews.com started coverage on shares of NeuroMetrix (NASDAQ:NURO) in a report released on Thursday. The brokerage set a “sell” rating on the medical device company’s stock.

NeuroMetrix Price Performance

Shares of NURO opened at $4.42 on Thursday. NeuroMetrix has a 1 year low of $2.66 and a 1 year high of $4.73. The company has a 50 day simple moving average of $4.28 and a two-hundred day simple moving average of $4.11. The firm has a market cap of $9.08 million, a P/E ratio of -0.96 and a beta of 2.15.

Institutional Investors Weigh In On NeuroMetrix

A hedge fund recently bought a new stake in NeuroMetrix stock. GTS Securities LLC bought a new stake in NeuroMetrix, Inc. (NASDAQ:NURO) in the fourth quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm bought 22,759 shares of the medical device company’s stock, valued at approximately $90,000. GTS Securities LLC owned approximately 1.12% of NeuroMetrix as of its most recent filing with the Securities & Exchange Commission. 19.40% of the stock is owned by institutional investors and hedge funds.

About NeuroMetrix

NeuroMetrix, Inc, a commercial stage neurotechnology company, engages in designing, building, and marketing medical devices that stimulate and analyze nerve response for diagnostic and therapeutic purposes in the United States, Europe, Japan, and China. Its marketed products include DPNCheck, a nerve conduction test that is used to evaluate peripheral neuropathies, such as diabetic peripheral neuropathy; Quell, a wearable device for symptomatic relief and management of chronic pain; and ADVANCE system offers services to device and provide disposable electrodes to a customer base of hand surgeons and manufacturers for industrial health use.